Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Neovascular AMD”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Ended earlyNCT01944839
What this trial is testing

Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy

Who this might be right for
Age-Related Macular Degeneration
Ophthotech Corporation 619
Early research (Phase 1)Study completedNCT02591914
What this trial is testing

An Open-Label Investigator Sponsored Trial to Investigate the Safety, Tolerability and Development of Subfoveal Fibrosis By Intravitreal Administration of Altering Regimens of Fovista and Anti-VEGF Therapy in Subjects With Neovascular Age-Related Macular Degeneration

Who this might be right for
Neovascular Age-Related Macular Degeneration
Retinal Consultants of Arizona 30
Testing effectiveness (Phase 2)Ended earlyNCT01025232
What this trial is testing

Intravitreal Injections of 2.0mg Ranibizumab in Subjects With Chronic Fluid On OCT Post Multiple Injections With Ranibizumab (Super-dose Anti-VEgf SAVE Trial)

Who this might be right for
Age Related Macular DegenerationChoroidal Neovascular MembraneSubfoveal Neovascular Age-Related Macular Degeneration+2 more
David M. Brown, M.D. 88
Large-scale testing (Phase 3)Study completedNCT06190093
What this trial is testing

A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)

Who this might be right for
Neovascular Age-related Macular DegenerationAge-Related Macular DegenerationWet Macular Degeneration
Outlook Therapeutics, Inc. 400
Large-scale testing (Phase 3)Study completedNCT02611778
What this trial is testing

Efficacy and Safety of the Biosimilar Ranibizumab FYB201 in Comparison to Lucentis in Patients With Neovascular Age-related Macular Degeneration

Who this might be right for
Age-related Macular Degeneration (AMD)
Bioeq GmbH 712
Not applicableStudy completedNCT05111743
What this trial is testing

Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (Komodo Health)

Who this might be right for
Age-related Macular Degeneration (AMD)
Novartis Pharmaceuticals 9,261
Large-scale testing (Phase 3)Study completedNCT00590694
What this trial is testing

Lucentis for Age-related Macular Degeneration Pigment Epithelial Detachments

Who this might be right for
Age-related Macular DegenerationPigment Epithelial DetachmentNeovascular Macular Degeneration+1 more
Pacific Eye Associates 15
Post-approval studies (Phase 4)Study completedNCT02321839
What this trial is testing

Evaluation of the Usefulness of a Treat and Extend Regimen Using Ranibizumab for Neovascular AMD.

Who this might be right for
Neovascular Age-related Macular Degeneration
Nagoya City University 78
Not applicableStudy completedNCT03411941
What this trial is testing

Evaluate the Effectiveness of Intravitreal (IVT) Aflibercept Injection in Clinical Practice in naïve Patients With Neovascular Age-related Macular Degeneration (nAMD)

Who this might be right for
Macular Degeneration
Bayer 116
Not applicableLooking for participantsNCT03577041
What this trial is testing

Medico-economic Evaluation of Anti-VEGF Treatments in the Treatment of naïve Age-related Macular Degeneration (AMD): a Model Adapted to the French Context

Who this might be right for
Age-related Macular Degeneration (AMD)
Centre Hospitalier Universitaire, Amiens 600
Post-approval studies (Phase 4)Study completedNCT01775124
What this trial is testing

Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration)

Who this might be right for
Neovascular Age-related Macular Degeneration
Novartis Pharmaceuticals 332
Large-scale testing (Phase 3)Looking for participantsNCT06847542
What this trial is testing

36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD

Who this might be right for
Neovascular Age-related Macular Degeneration
Hoffmann-La Roche 250
Early research (Phase 1)Study completedNCT05639530
What this trial is testing

A Dose Escalation Study of IBI333 in Subjects With Neovascular Age-related Macular Degeneration

Who this might be right for
Neovascular Age-related Macular Degeneration
Innovent Biologics (Suzhou) Co. Ltd. 17
Large-scale testing (Phase 3)Active Not RecruitingNCT06495918
What this trial is testing

Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration

Who this might be right for
Neovascular Age-related Macular Degeneration
Ocular Therapeutix, Inc. 825
Testing effectiveness (Phase 2)Study completedNCT04832724
What this trial is testing

RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular Degeneration (nAMD)

Who this might be right for
Neovascular Age-related Macular DegenerationWet Macular DegenerationWet Age-related Macular Degeneration
AbbVie 60
Testing effectiveness (Phase 2)Ended earlyNCT02348359
What this trial is testing

X-82 to Treat Age-related Macular Degeneration

Who this might be right for
Age-Related Macular Degeneration (AMD)Macular DegenerationExudative Age-related Macular Degeneration+5 more
Tyrogenex 157
Testing effectiveness (Phase 2)Study completedNCT02510794
What this trial is testing

Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration

Who this might be right for
Macular Degeneration
Genentech, Inc. 225
Testing effectiveness (Phase 2)Active Not RecruitingNCT04514653
What this trial is testing

RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)

Who this might be right for
Neovascular Age-Related Macular Degeneration (nAMD)
AbbVie 146
Testing effectiveness (Phase 2)Study completedNCT04567303
What this trial is testing

Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration

Who this might be right for
Macular Degeneration
Hoffmann-La Roche 177
Post-approval studies (Phase 4)Study completedNCT05710471
What this trial is testing

Treatment of Recalcitrant Neovascular AMD Using Brolocizumab With Immediate T&E

Who this might be right for
Age-Related Macular Degeneration
The University of Hong Kong 30
Next Page